Related Experiment Video
Updated: Apr 23, 2026

06:59
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
10.5K
Recurrent Hypoglycemia in Two Late-Preterm Infants With Transitional Disorder of Glucose Mobilization-Case Series
Suresh Chandran1,2,3,4, Yu Shan Ting1, Skanthakumar Abhirami1
1Department of Neonatology KK Women's and Children's Hospital Singapore.
Clinical Case Reports
|April 22, 2026
Summary
Recurrent hypoglycemia in preterm infants can stem from temporary glucose mobilization issues, not hyperinsulinism. Diazoxide treatment and glucagon tests can help identify hepatic enzyme immaturity in these cases.
Area of Science:
- Neonatal Medicine
- Pediatric Endocrinology
- Metabolic Disorders
Background:
- Recurrent hypoglycemia is a significant concern in at-risk infants.
- Hyperinsulinism is a common cause, but other etiologies exist.
Purpose of the Study:
- To report on two preterm infants with recurrent nonhyperinsulinemic hypoglycemia.
- To highlight the role of transient glucose mobilization impairment.
- To discuss the diagnostic utility of glucagon stimulation tests and genetic testing.
Main Methods:
- Case report of two preterm infants.
- Clinical evaluation including recurrent hypoglycemia assessment.
- Glucagon stimulation test performance.
- Genetic testing for glycogen storage disorders.
Main Results:
- Both infants presented with recurrent nonhyperinsulinemic hypoglycemia.
- Diagnosis was attributed to transient impairment of glucose mobilization.
- Diazoxide was administered for treatment.
- Inadequate response to glucagon stimulation suggested hepatic enzyme immaturity.
- Genetic testing for glycogen storage disorders was negative.
Conclusions:
- Transient impairment of glucose mobilization can cause recurrent hypoglycemia in preterm infants.
- Diazoxide is a viable treatment option.
- Glucagon stimulation tests and genetic testing aid in differentiating causes of hypoglycemia and identifying hepatic enzyme immaturity.
Related Concept Videos
Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Hypoglycemia
5
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
5
Glucose Transporters
15.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.1K
Pathophysiology of Diabetes
3.9K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.9K
Diabetes Mellitus: Type 2 and Gestational
4.8K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.8K
Type II Diabetes II: Pathophysiology
6
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
6

